Movatterモバイル変換

[0]ホーム
URL:

Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
Thehttps:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

NIH NLM Logo
Log inShow account info
Access keysNCBI HomepageMyNCBI HomepageMain ContentMain Navigation
pubmed logo
Advanced Clipboard
User Guide

Full text links

Springer full text link Springer Free PMC article
Full text links

Actions

Share

.2015 Mar;232(6):1039-47.
doi: 10.1007/s00213-014-3739-3. Epub 2014 Sep 17.

Hallucinogen-like effects of 2-([2-(4-cyano-2,5-dimethoxyphenyl) ethylamino]methyl)phenol (25CN-NBOH), a novel N-benzylphenethylamine with 100-fold selectivity for 5-HT₂A receptors, in mice

Affiliations

Hallucinogen-like effects of 2-([2-(4-cyano-2,5-dimethoxyphenyl) ethylamino]methyl)phenol (25CN-NBOH), a novel N-benzylphenethylamine with 100-fold selectivity for 5-HT₂A receptors, in mice

William E Fantegrossi et al. Psychopharmacology (Berl).2015 Mar.

Abstract

Rationale: 2-([2-(4-cyano-2,5-dimethoxyphenyl)ethylamino]methyl)phenol (25CN-NBOH) is structurally similar to N-benzyl substituted phenethylamine hallucinogens currently emerging as drugs of abuse. 25CN-NBOH exhibits dramatic selectivity for 5-HT2A receptors in vitro, but has not been behaviorally characterized.

Objective: 25CN-NBOH was compared to the traditional phenethylamine hallucinogen R(-)-2,5-dimethoxy-4-iodoamphetamine (DOI) using mouse models of drug-elicited head twitch behavior and drug discrimination.

Methods: Drug-elicited head twitches were quantified for 10 min following administration of various doses of either DOI or 25CN-NBOH, with and without pretreatments of 0.01 mg/kg 5-HT2A antagonist M100907 or 3.0 mg/kg 5-HT2C antagonist RS102221. The capacity of 25CN-NBOH to attenuate DOI-elicited head twitch was also investigated. Mice were trained to discriminate DOI or M100907 from saline, and 25CN-NBOH was tested for generalization.

Results: 25CN-NBOH induced a head twitch response in the mouse that was lower in magnitude than that of DOI, blocked by M100907, but not altered by RS102221. DOI-elicited head twitch was dose-dependently attenuated by 25CN-NBOH pretreatment. 25CN-NBOH produced an intermediate degree of generalization (55 %) for the DOI training dose, and these interoceptive effects were attenuated by M100907. Finally, 25CN-NBOH did not generalize to M100907 at any dose, but ketanserin fully substituted in these animals.

Conclusions: 25CN-NBOH was behaviorally active, but less effective than DOI in two mouse models of hallucinogenic effects. The effectiveness with which M100907 antagonized the behavioral actions of 25CN-NBOH strongly suggests that the 5-HT2A receptor is an important site of agonist action for this compound in vivo.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Structures of 25CN-NBOH (left) and R(−)-DOI (right).
Figure 2
Figure 2
Biphasic dose-dependent effects of R(−)-DOI (black circles) and 25CN-NBOH (grey triangles) on head twitch behavior in NIH Swiss mice. Black diamonds represent 25CN-NBOH-elicited head twitch behavior after pretreatment with 0.01 mg/kg M100907, while the white inverted triangle represents 25CN-NBOH-elicited head twitch behavior following pretreatment with 3.0 mg/kg RS102221. Asterisks indicate significant differences from saline, hash marks indicate significant differences from the same dose of DOI, and bullseyes indicate differences from the same dose of 25CN-NBOH (without antagonist pretreatment). Abscissa: Dose of DOI or 25CN-NBOH, expressed as mg/kg on a log scale. Ordinate: Mean head twitches recorded over a 10 minute observation period.
Figure 3
Figure 3
Head twitch behavior elicited by 1.0 mg/kg R(−)-DOI following pretreatment with saline (white circle) or various doses of 25CN-NBOH (black circles.) Asterisks indicate significant differences from saline pretreatment, while hash marks indicate significant differences from lower pretreatment doses of 25CN-NBOH.Abscissa: Dose of 25CN-NBOH, expressed as mg/kg on a log scale, and administered as a pretreatment 15 min prior to R(−)-DOI injection.Ordinate: as described in Figure 2.
Figure 4
Figure 4
Left panel - Discriminative stimulus effects of R(−)-DOI (black circles), 25CN-NBOH (grey triangles), and 25CN-NBOH following pretreatment with M100907 (white triangles) in mice trained to discriminate 0.3 mg/kg R(−)-DOI from saline. Asterisks indicate significant differences from saline, while hash marks indicate significant differences from the DOI training dose. Abscissa: Cumulative dose of DOI or 25CN-NBOH expressed as mg/kg on a log scale. Ordinate: percent of total responses emitted on the R(−)-DOI-appropriate lever.Right panel – Response rates (per second) obtained during substitution testing with cumulative doses of R(−)-DOI and 25CN-NBOH. Fractions represent number of animals completing the response requirement at a given dose, if less than 6. Abscissa: ‘S1–S4' represents four discrete saline injections administered across four components of a substitution session. Numbers refer to cumulative doses of drugs during substitution sessions, expressed as mg/kg on a log scale. Ordinate: response rates, expressed as lever presses per second.
Figure 5
Figure 5
Left panel - Discriminative stimulus effects of M100907 (black circles), ketanserin (white circles) and 25CN-NBOH (grey triangles) in mice trained to discriminate 0.1 mg/kg M100907 from saline. Asterisks indicate significant differences from saline, while hash marks indicate significant differences from the M100907 training dose. Abscissa and ordinate as described in Figure 4.Right panel – Response rates (per second) obtained during substitution testing with cumulative doses of M100907, ketanserin and 25CN-NBOH. Abscissa and ordinate as described in Figure 4.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Advisory Council on the Misuse of Drugs (ACMD) “NBOMe” compounds: A review of the evidence of use and harm. [Accessed 03 July 2014];2013 Available at:https://www.gov.uk/government/uploads/system/uploads/attachment_data/fil....
    1. Blaazer AR, Smid P, Kruse CG. Structure-activity relationships of phenylalkylamines as agonist ligands for 5-HT(2A) receptors. Chem Med Chem. 2008;3(9):1299–1309. - PubMed
    1. Braden MR, Parrish JC, Naylor JC, Nichols DE. Molecular interaction of serotonin 5-HT2A receptor residues Phe339(6.51) and Phe340(6.52) with superpotent N-benzyl phenethylamine agonists. Mol Pharmacol. 2006;70(6):1956–1964. - PubMed
    1. Canal CE, Morgan D. Head-twitch response in rodents induced by the hallucinogen 2,5-dimethoxy-4-iodoamphetamine: a comprehensive history, a re-evaluation of mechanisms, and its utility as a model. Drug Test Anal. 2012;4(7–8):556–576. - PMC - PubMed
    1. Fantegrossi WE, Murnane KS, Reissig CJ. The behavioral pharmacology of hallucinogens. Biochem Pharmacol. 2008;75(1):17–33. - PMC - PubMed

Publication types

MeSH terms

Substances

Related information

Grants and funding

LinkOut - more resources

Full text links
Springer full text link Springer Free PMC article
Cite
Send To

NCBI Literature Resources

MeSHPMCBookshelfDisclaimer

The PubMed wordmark and PubMed logo are registered trademarks of the U.S. Department of Health and Human Services (HHS). Unauthorized use of these marks is strictly prohibited.

[8]ページ先頭
©2009-2025 Movatter.jp